Coherus Oncology, Inc. Annual Report: A Look at Their Year (Fiscal Year Ending December 31, 2025)

This summary distills key insights from Coherus Oncology, Inc.'s SEC filing for the fiscal year ending December 31, 2025, with comparisons to 2024 and 2023 where relevant. We highlight the company's strategic activities and financial framework.

Business Overview

Coherus Oncology, Inc. has strategically transformed into an oncology-focused biopharmaceutical company. The company significantly reshaped its product portfolio in 2025 and 2024. They generate revenue from products like Loqtorzi (Toripalimab) and Udenyca. Notably, the company divested several key assets: selling its Yusimry Immunology Franchise in June 2024 and its Cimerli Ophthalmology Franchise in March 2024. They also classified the Udenyca business as a discontinued operation. These moves signal a strategic pivot to streamline operations and concentrate on their oncology pipeline and products such as Loqtorzi. The highly regulated biopharmaceutical industry significantly impacts the company's operations, particularly drug approval processes and healthcare policy.

Financial Performance

Coherus generated revenue from Loqtorzi and Udenyca in both 2025 and 2024. The company incurred typical biopharma expenses, such as Research and Development (R&D) and Selling, General, and Administrative (SG&A) costs. Because Coherus divested the Yusimry, Cimerli, and Udenyca businesses, future financial comparisons must account for these discontinued operations, which will significantly alter the company's financial profile.

Risk Factors

Investors should consider several key risks that could affect Coherus's financial health and stock price:

• Customer Concentration: In 2025 and 2024, a few major distributors—McKesson, Cencora Inc., and Cardinal—generated a substantial portion of sales revenue. This heavy reliance on a small customer base creates risk if relationships change or if these customers encounter their own difficulties.
• Debt Levels: Coherus carries significant financial obligations, including Convertible Senior Subordinated Notes due in 2026 and Term Loans due in 2029 from Biopharma Credit Investments V GP LLC. These debts could impact the company's liquidity and financial flexibility.
• R&D Success: As a biopharma company, Coherus's future success depends heavily on successful research and development, including completing clinical trials and securing regulatory approvals for new therapies.
• Strategic Transition: While potentially beneficial, the ongoing divestitures and pivot to an oncology-focused business carry execution risks. These include challenges with integration, market acceptance of remaining products, and the financial impact of these transactions.
• Contingent Consideration: Coherus has contingent consideration liabilities—future payments often tied to the performance of acquired assets or milestones. These obligations add financial uncertainty and could impact future cash flows.
• Competition: The highly competitive oncology market features numerous established and emerging players. Loqtorzi and any future oncology products must compete effectively on efficacy, safety, and price to succeed.
• Regulatory Environment: As a biopharmaceutical company, Coherus operates under extensive government regulation covering product approval, manufacturing, marketing, and pricing. Changes in these regulations could adversely affect the business.

Management Discussion (MD&A Highlights)

Management's discussion highlights the significant strategic transformation Coherus undertook in fiscal years 2025 and 2024. The company deliberately pivoted to become an oncology-focused biopharmaceutical entity. This strategic shift included divesting non-oncology assets, such as the Yusimry Immunology Franchise and the Cimerli Ophthalmology Franchise in 2024, and classifying the Udenyca business as a discontinued operation. These actions aim to streamline operations and concentrate resources on the oncology pipeline and products like Loqtorzi.

Operationally, the company continued to generate revenue from Loqtorzi and Udenyca, while managing R&D and SG&A expenses typical for the industry. Management identified significant customer concentration as a key challenge, with a few major distributors generating a substantial portion of sales revenue.

Regarding liquidity and capital resources, management emphasizes the company's debt obligations, including convertible senior subordinated notes and term loans. The subsequent public offering in February 2026 provided critical additional capital. Management would discuss this offering as a means to fund ongoing operations, R&D, and strengthen the balance sheet. The company also manages contingent consideration liabilities and lease obligations.

Financial Health

Coherus carries significant debt, including Convertible Senior Subordinated Notes due in 2026 (at 1.5% interest) and Term Loans due in 2029 from Biopharma Credit Investments V GP LLC. They also have operating and finance lease liabilities. A significant event occurred in February 2026: Coherus completed a public offering of shares. This offering raised additional capital after the fiscal year-end, which could prove crucial for enhancing liquidity, funding ongoing operations and R&D, or managing existing debt. The company also holds contingent consideration liabilities, representing potential future financial obligations.

Future Outlook

Coherus's future outlook centers on its oncology pipeline and the continued commercialization of products like Loqtorzi. The strategic pivot to an oncology-focused business will guide future investments and operational decisions. The public offering completed in February 2026 provides fresh capital. Coherus anticipates using these funds to support ongoing R&D, commercialization activities for its oncology portfolio, and strengthen its overall financial position. Successful management of debt obligations and effective integration and execution of its new, focused oncology strategy will be key to the company's future.

Competitive Position

Coherus Oncology, Inc. strategically focuses its competitive efforts within the oncology market, primarily with products like Loqtorzi. By divesting its biosimilar immunology (Yusimry) and ophthalmology (Cimerli) franchises and classifying the Udenyca business as a discontinued operation, Coherus deliberately narrowed its competitive landscape. This move concentrates resources on areas of perceived strength and growth potential. The company also collaborates and out-licenses with partners like GSK and Novartis Institutes (via Surface Oncology Inc.). These partnerships help Coherus leverage external expertise, expand product reach, and enhance its competitive stance in oncology. The intense competitive landscape in oncology demands continuous innovation and effective commercialization strategies.